Literature DB >> 6305522

Pharmacokinetics of ftorafur after intravenous and oral administration.

M I Anttila, E A Sotaniemi, M I Kairaluoma, R E Mokka, H T Sundquist.   

Abstract

The pharmacokinetics of ftorafur (FT), an antineoplastic agent, has been studied in seven cancer patients by determining concentrations of the unchanged compound in serum after single IV and PO doses of 2 g FT. Serum drug concentrations were determined by a new quantitative thin-layer chromatographic method. After IV administration, the mean half-lives of the distribution phase and elimination phase were 1.0 h and 7.6 h, respectively. Total serum clearance was 69 ml/h . kg and the apparent volume of distribution was 0.66 l/kg. Following PO administration there was a short lag-time, 11 min, before the appearance of FT in peripheral serum, and the maximum concentration in peripheral serum was achieved in 3.2 h. Oral absorption was complete and no significant first-pass metabolism could be observed. FT elimination, measured in serum taken from the portal vein and a peripheral vein, occurred substantially at the same rate after IV and PO administration. In contrast, after the PO dose FT appeared in the portal serum significantly earlier than in the peripheral serum, resulting in a difference of 1.7 h in the time of maximum serum concentration. This indicates fast gastrointestinal absorption of FT but hepatic retention (without metabolism) before the appearance of FT in the peripheral serum.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305522     DOI: 10.1007/bf00255750

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  In vitro biological evaluation of the R and S isomers of 1-(Tetrahydrofuran-2-yl)-5-fluorouracil.

Authors:  J P Horwitz; J J McCormick; K D Philips; V M Maher; J R Otto; D Kessel; J Zemlicka
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

2.  The disposition of ftorafur in rats after intravenous administration.

Authors:  A M Cohen
Journal:  Drug Metab Dispos       Date:  1975 Jul-Aug       Impact factor: 3.922

3.  Pharmacokinetics and metabolism of ftorafur in man.

Authors:  J L Au; A T Wu; M A Friedman; W Sadée
Journal:  Cancer Treat Rep       Date:  1979-03

4.  GLC determination for ftorafur in biological fluids.

Authors:  E B Hills; V C Godefroi; I A O'Leary; M Burke; D Andrzejewski; W Brukwinski; J P Horwitz
Journal:  J Pharm Sci       Date:  1977-10       Impact factor: 3.534

5.  High-pressure liquid chromatographic analysis of ftorafur and its metabolites in biological fluids.

Authors:  J A Benvenuto; K Lu; T L Loo
Journal:  J Chromatogr       Date:  1977-04-01

6.  Quantitative gas-liquid chromatographic determination of ftorafur and 5-fluorouracil in biological specimens.

Authors:  C Pantarotto; R Fanelli; S Filippeschi; T Facchinetti; F Spreafico; M Salmona
Journal:  Anal Biochem       Date:  1979-09-01       Impact factor: 3.365

7.  To biological activity of antitumour antimetabolite "ftorafur".

Authors:  A Z Smolyanskaya; O A Tugarinov
Journal:  Neoplasma       Date:  1972       Impact factor: 2.575

8.  Determination of ftorafur and 5-fluorouracil levels in plasma and urine.

Authors:  A T Wu; H J Schwandt; C Finn; W Sadée
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-05

9.  Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans.

Authors:  J A Benvenuto; K Lu; S W Hall; R S Benjamin; T L Loo
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

10.  High-pressure liquid chromatographic determination of ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur.

Authors:  T Marunaka; Y Umeno; K Yoshida; M Nagamachi; Y Minami; S Fujii
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

View more
  6 in total

Review 1.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

Review 2.  Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Authors:  Frederik E Stuurman; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

3.  Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination.

Authors:  Y Maehara; H Takeuchi; T Oshiro; I Takahashi; S Inutsuka; H Baba; S Kohnoe; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Phase II trial of UFT in advanced colorectal and gastric cancer.

Authors:  S T Malik; D Talbot; P I Clarke; R Osborne; R Reznek; P F Wrigley; M L Slevin
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

5.  'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.

Authors:  J Bennouna; H Perrier; B Paillot; F Priou; J H Jacob; M Hebbar; S Bordenave; J F Seitz; F Cvitkovic; E Dorval; K Malek; D Tonelli; J Y Douillard
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

6.  Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy.

Authors:  Satoshi Nishino; Ayumi Itoh; Hiroshi Matsuoka; Kotaro Maeda; Shingo Kamoshida
Journal:  Mol Clin Oncol       Date:  2013-04-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.